Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A: results from the botulinum toxin for the upper limb after stroke (BoTULS) trial.
Stroke imposes significant burdens on health services and society, and as such there is a growing need to assess the cost-effectiveness of stroke treatment to ensure maximum benefit is derived from limited resources. This study compared the cost-effectiveness of treating post-stroke upper limb spasticity with botulinum toxin type A plus an upper limb therapy programme against the therapy programme alone. Data on resource use and health outcomes were prospectively collected for 333 patients with post-stroke upper limb spasticity taking part in a randomized trial and combined to estimate the incremental cost per quality adjusted life year (QALY) gained of botulinum toxin type A plus therapy relative to therapy alone. The base case incremental cost-effectiveness ratio (ICER) of botulinum toxin type A plus therapy was £93,500 per QALY gained. The probability of botulinum toxin type A plus therapy being cost-effective at the England and Wales cost-effectiveness threshold value of £20,000 per QALY was 0.36. The point estimates of the ICER remained above £20,000 per QALY for a range of sensitivity analyses, and the probability of botulinum toxin type A plus therapy being cost-effective at the threshold value did not exceed 0.39, regardless of the assumptions made.
School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK. p.shackley@sheffield.ac.uk
Phil
P
Shackley
Lisa
L
Shaw
Christopher
C
Price
Frederike
F
van Wijck
Michael
M
Barnes
Laura
L
Graham
Gary A
GA
Ford
Nick
N
Steen
Helen
H
Rodgers
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000191:economics*; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D006801:Humans; D009128:Muscle Spasticity / Q000191:economics* / Q000209:etiology / Q000628:therapy; D026741:Physical Therapy Modalities; D019057:Quality-Adjusted Life Years; D020521:Stroke / Q000150:complications / Q000191:economics* / Q000628:therapy; D034941:Upper Extremity
D019274:Botulinum Toxins, Type A